Tilray Brands Soars 11.96% on U.S. Reclassification Hopes

On August 12, 2025, Tilray Brands experienced a significant pre-market surge, rising by 11.96%. This notable increase can be attributed to the potential regulatory changes in the cannabis industry, particularly the possibility of the U.S. government reclassifying marijuana to Schedule III. This reclassification would move marijuana to a category for drugs with accepted medical uses and lower abuse potential, which could significantly impact the industry.

The surge in Tilray Brands' stock is driven by the potential regulatory changes in the cannabis industry. The possibility of the U.S. government reclassifying marijuana to Schedule III has sparked investor optimism. This reclassification could provide relief from Internal Revenue Code Section 280E, which currently imposes significant tax burdens on cannabis companies. The potential easing of federal restrictions and the boost in investor confidence have contributed to the stock's surge.

President Trump's consideration of reclassifying marijuana has been a key driver of the recent surge in Tilray Brands' stock. Reports of a possible marijuana reclassification by Trump have fueled investor optimism, leading to a significant increase in the stock's price. This regulatory optimism, combined with the potential for streamlined cannabis sales and reduced regulatory burdens, has amplified investor confidence in the company.